as 03-28-2025 4:00pm EST
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Founded: | 1995 | Country: | United States |
Employees: | N/A | City: | LAKE FOREST |
Market Cap: | 78.3M | IPO Year: | 1997 |
Target Price: | $3.08 | AVG Volume (30 days): | 411.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.23 | EPS Growth: | N/A |
52 Week Low/High: | $0.68 - $1.80 | Next Earning Date: | 03-12-2025 |
Revenue: | $124,961,000 | Revenue Growth: | -17.83% |
Revenue Growth (this year): | 0.96% | Revenue Growth (next year): | 12.72% |
ASRT Breaking Stock News: Dive into ASRT Ticker-Specific Updates for Smart Investing
ACCESS Newswire
8 days ago
GlobeNewswire
9 days ago
Simply Wall St.
15 days ago
Thomson Reuters StreetEvents
16 days ago
GuruFocus.com
16 days ago
Associated Press Finance
17 days ago
GlobeNewswire
17 days ago
GlobeNewswire
24 days ago
The information presented on this page, "ASRT Assertio Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.